The Rising Trend in the Use of Patient-Reported Outcomes in Atrial Fibrillation Clinical Trials
Atrial fibrillation (AF), already the most prevalent clinical arrhythmia, is increasing in prevalence1. It is associated with adverse outcomes that significantly impact the quality of life (QoL) experienced by patients. Thus, the accurate evaluation of QoL is an emerging part of the assessment of AF patients2. Several tools have arisen to evaluate clinically relevant endpoints. Patient-reported outcomes (PROs) are now commonly used to evaluate QoL in clinical trials3. Additionally, patient-reported experience measures (PREMs), though different from PROs, also focus on satisfaction with care delivery as well as patient and public involvement (PPI).